Alligator Bioscience To Present Positive Phase 2 Mitazalimab

OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median 12.5 months) and overall survival (median 14.3 months) support continued development of mitazalimab in a randomized confir...

Related Keywords

Chicago , Illinois , United States , Sweden , Hall On , Orebro , American , Peter Ellmark , Jean Luc Van Laethem , Frank Hoerning Andersen , Sumeet Ambarkhane , Aptevo Therapeutics Inc , Orion Corporation , Market Research , American Society Of Clinical Oncology , Biotheus Inc , Cohesion Bureau , Shanghai Henlius Biotech Inc , Alligator Bioscience , Clinical Oncology , Annual Meeting , Objective Response Rate , Response Evaluation Criteria , Solid Tumors , Overall Survival , Gastrointestinal Cancer Gastroesophageal , Shanghai Henlius Biotech , Nasdaq Stockholm ,